ALZN
Closed
Alzamend Neuro Inc
2.92
+0.01 (+0.34%)
Last Update: 01 Jul 2025 23:01:00
Yesterday: 2.91
Day's Range: 2.8101 - 2.92
Send
sign up or login to leave a comment!
When Written:
0.425
Alzamend Neuro Inc. is a biopharmaceutical company that focuses on developing innovative treatments for Alzheimer's disease and other neurodegenerative disorders. The company's mission is to improve the lives of patients suffering from these debilitating conditions by developing safe and effective therapies that target the underlying causes of the disease.
Alzamend Neuro's lead product candidate is AL001, which is a patented oral small molecule drug designed to target the underlying cause of Alzheimer's disease. The drug works by inhibiting the formation and accumulation of toxic beta-amyloid plaques in the brain, which are thought to be a major contributor to the disease.
In addition to AL001, Alzamend Neuro is also developing a diagnostic tool called AL002, which is designed to detect the presence of beta-amyloid plaques in the brain before symptoms of Alzheimer's disease appear. This early detection tool could help identify patients who are at risk for developing the disease and enable earlier intervention and treatment.
Alzamend Neuro is headquartered in Tampa, Florida, and was founded in 2016. The company is led by a team of experienced biopharmaceutical executives and scientists who are dedicated to advancing the development of new therapies for Alzheimer's disease and other neurodegenerative disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Alzamend Neuro's lead product candidate is AL001, which is a patented oral small molecule drug designed to target the underlying cause of Alzheimer's disease. The drug works by inhibiting the formation and accumulation of toxic beta-amyloid plaques in the brain, which are thought to be a major contributor to the disease.
In addition to AL001, Alzamend Neuro is also developing a diagnostic tool called AL002, which is designed to detect the presence of beta-amyloid plaques in the brain before symptoms of Alzheimer's disease appear. This early detection tool could help identify patients who are at risk for developing the disease and enable earlier intervention and treatment.
Alzamend Neuro is headquartered in Tampa, Florida, and was founded in 2016. The company is led by a team of experienced biopharmaceutical executives and scientists who are dedicated to advancing the development of new therapies for Alzheimer's disease and other neurodegenerative disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!